Janux Therapeutics (NASDAQ:JANX) Shares Down 4.2% – Here’s What Happened

by · The Cerbat Gem

Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) was down 4.2% on Monday . The stock traded as low as $43.07 and last traded at $43.31. Approximately 103,171 shares were traded during trading, a decline of 85% from the average daily volume of 706,741 shares. The stock had previously closed at $45.21.

Analyst Ratings Changes

JANX has been the topic of a number of research analyst reports. Leerink Partnrs raised shares of Janux Therapeutics to a “strong-buy” rating in a research report on Friday, November 22nd. UBS Group initiated coverage on Janux Therapeutics in a report on Thursday, October 24th. They issued a “buy” rating and a $69.00 price target on the stock. William Blair restated an “outperform” rating on shares of Janux Therapeutics in a report on Tuesday. Leerink Partners upped their target price on Janux Therapeutics from $79.00 to $91.00 and gave the stock an “outperform” rating in a research report on Tuesday. Finally, HC Wainwright lifted their price target on shares of Janux Therapeutics from $63.00 to $70.00 and gave the company a “buy” rating in a research report on Tuesday. One research analyst has rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Janux Therapeutics has a consensus rating of “Buy” and an average price target of $77.90.

Get Our Latest Analysis on JANX

Janux Therapeutics Stock Up 49.0 %

The company has a market capitalization of $3.14 billion, a P/E ratio of -51.16 and a beta of 3.29. The business’s 50-day moving average is $49.60 and its two-hundred day moving average is $45.72.

Janux Therapeutics (NASDAQ:JANX – Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.18). The firm had revenue of $0.44 million for the quarter, compared to the consensus estimate of $1.50 million. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. Janux Therapeutics’s quarterly revenue was down 82.6% on a year-over-year basis. Analysts predict that Janux Therapeutics, Inc. will post -1.35 EPS for the current year.

Insiders Place Their Bets

In related news, CEO David Alan Campbell sold 25,000 shares of Janux Therapeutics stock in a transaction that occurred on Friday, September 27th. The shares were sold at an average price of $46.31, for a total value of $1,157,750.00. Following the sale, the chief executive officer now owns 307,054 shares of the company’s stock, valued at approximately $14,219,670.74. The trade was a 7.53 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Ventures Xi L.P. Avalon sold 108,365 shares of the company’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $42.00, for a total value of $4,551,330.00. Following the completion of the transaction, the insider now owns 3,162,851 shares in the company, valued at approximately $132,839,742. The trade was a 3.31 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 460,610 shares of company stock valued at $21,583,666. Insiders own 29.40% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Plato Investment Management Ltd boosted its holdings in Janux Therapeutics by 18.7% in the 3rd quarter. Plato Investment Management Ltd now owns 1,186 shares of the company’s stock worth $54,000 after buying an additional 187 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Janux Therapeutics by 21.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock worth $87,000 after acquiring an additional 339 shares during the period. Amalgamated Bank grew its position in shares of Janux Therapeutics by 61.1% in the second quarter. Amalgamated Bank now owns 970 shares of the company’s stock valued at $41,000 after purchasing an additional 368 shares in the last quarter. Summit Securities Group LLC bought a new stake in shares of Janux Therapeutics during the 2nd quarter valued at $29,000. Finally, Virtu Financial LLC lifted its holdings in Janux Therapeutics by 48.0% during the 3rd quarter. Virtu Financial LLC now owns 7,463 shares of the company’s stock worth $339,000 after purchasing an additional 2,419 shares in the last quarter. Hedge funds and other institutional investors own 75.39% of the company’s stock.

About Janux Therapeutics

(Get Free Report)

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

Featured Stories